| Product dosage: 60caps | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 2 | $28.27 | $56.55 (0%) | 🛒 Add to cart |
| 3 | $26.59 | $84.82 $79.77 (6%) | 🛒 Add to cart |
| 4 | $25.50 | $113.09 $101.99 (10%) | 🛒 Add to cart |
| 5 | $24.84 | $141.37 $124.20 (12%) | 🛒 Add to cart |
| 6 | $24.57 | $169.64 $147.43 (13%) | 🛒 Add to cart |
| 7 | $24.23 | $197.91 $169.64 (14%) | 🛒 Add to cart |
| 8 | $24.11 | $226.19 $192.86 (15%) | 🛒 Add to cart |
| 9 | $23.90 | $254.46 $215.08 (15%) | 🛒 Add to cart |
| 10 | $23.83
Best per bottle | $282.73 $238.30 (16%) | 🛒 Add to cart |
Similar products
More info:
Albuterol and Hyperkalemia: Essential Cardiac Risk Management
For cardiac patients, understanding the nuanced relationship between albuterol and serum potassium levels is not merely academic—it is a critical component of safe pharmacotherapy. This comprehensive guide delivers evidence-based insights into the mechanisms, monitoring protocols, and clinical management strategies necessary to mitigate the risk of hypokalemia and its subsequent cardiac complications when using this common bronchodilator. Empower yourself with the knowledge to optimize therapeutic outcomes while safeguarding cardiovascular stability. Features Detailed exploration of the β2-adrenergic receptor mechanism on potassium shift Evidence-based clinical data on serum potassium reduction timelines and magnitude Specific risk stratification protocols for patients with pre-existing cardiac conditions Monitoring parameter frameworks including ECG correlation with potassium levels Comparative analysis of various albuterol delivery methods and potassium effects Clinical decision pathways for concomitant medication management Benefits Enables preemptive identification of patients at highest risk for clinically significant hypokalemia Provides clear monitoring parameters to prevent arrhythmogenic complications Supports appropriate dosing strategies that balance bronchodilation with cardiac safety Facilitates informed conversations between clinicians and patients about risk mitigation Reduces emergency department visits and hospitalizations related to adverse cardiac events Enhances confidence in managing complex patients with cardiorespiratory comorbidities Common use Albuterol, a short-acting β2-adrenergic receptor agonist, is primarily prescribed for the relief and prevention of bronchospasm in patients with reversible obstructive airway disease, including asthma and chronic obstructive pulmonary disease (COPD).
Albuterol Nebulizer Treatment: Fast-Acting Relief for Breathing Difficulties
Albuterol nebulizer treatment is a cornerstone of respiratory therapy, delivering rapid bronchodilation for patients experiencing acute or chronic breathing obstruction. This inhaled medication works by relaxing the smooth muscles lining the airways, making it easier to breathe within minutes of administration. It is commonly prescribed for conditions such as asthma, chronic obstructive pulmonary disease (COPD), and exercise-induced bronchospasm. Proper technique and adherence to dosing guidelines are critical for maximizing therapeutic efficacy while minimizing potential side effects.
Albuterol Sulfate HFA Inhaler: Fast-Acting Relief for Asthma and Bronchospasm
Albuterol Sulfate HFA Inhaler is a trusted, prescription-only bronchodilator designed for rapid relief of acute bronchospasm. It works by relaxing the muscles in the airways, allowing improved airflow within minutes of administration. This guide provides a comprehensive overview of its medical uses, proper dosing, safety considerations, and clinical benefits to support informed patient and provider decision-making. Features Contains albuterol sulfate, a short-acting beta2-adrenergic agonist (SABA) Hydrofluoroalkane (HFA) propellant, chlorofluorocarbon-free Delivers 90 mcg per actuation Compact, portable metered-dose inhaler (MDI) design Integrated dose counter to track remaining medication Compatible with valved holding chambers (spacers) for improved delivery Benefits Provides rapid relief from acute asthma symptoms and exercise-induced bronchospasm Helps restore normal breathing patterns within minutes of use Reduces frequency and severity of bronchospastic episodes Supports active lifestyles by preventing exercise-induced symptoms Minimizes emergency department visits through effective symptom management Enhances overall quality of life by improving respiratory function Common use Albuterol Sulfate HFA Inhaler is primarily indicated for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease, including asthma.
Deltasone: Effective Systemic Inflammation and Immune Response Control
Deltasone (prednisone) is a potent synthetic corticosteroid medication designed to manage a wide range of inflammatory and autoimmune conditions. By mimicking the effects of cortisol, a natural hormone produced by the adrenal glands, it exerts profound anti-inflammatory and immunosuppressive effects. This makes it a cornerstone therapy in both acute flare management and chronic disease control. Its ability to rapidly modulate the immune system provides clinicians with a powerful tool to alleviate symptoms, prevent tissue damage, and improve patient quality of life across numerous clinical scenarios.
Haridra: Advanced Turmeric Extract for Inflammation Relief
Haridra, derived from the botanical Curcuma longa, represents a scientifically-formulated, high-potency turmeric extract designed for targeted therapeutic use. Unlike conventional turmeric supplements, Haridra is standardized to contain a minimum of 95% curcuminoids—the primary bioactive compounds responsible for its extensive pharmacological benefits. Developed through rigorous extraction and purification processes, this product ensures optimal bioavailability and consistent dosing, making it a reliable choice for clinicians and health-conscious individuals seeking evidence-based natural interventions. Its application spans anti-inflammatory support, antioxidant defense, and metabolic modulation, backed by a growing body of preclinical and clinical research.
Optimized Asthma Control with Pulmicort and Ventolin Therapy
Combining Pulmicort (budesonide) and Ventolin (albuterol) represents a cornerstone of modern asthma management, offering both immediate symptom relief and long-term inflammatory control. This dual-therapy approach addresses the two primary pathological components of asthma—bronchospasm and airway inflammation—through complementary pharmacological mechanisms. When used appropriately under medical supervision, this combination provides superior asthma control compared to monotherapy, reduces exacerbation frequency, and improves overall quality of life for patients with persistent asthma symptoms. Features Contains budesonide (corticosteroid) for anti-inflammatory action Includes albuterol sulfate (short-acting beta-agonist) for bronchodilation Compatible with most nebulizer systems and metered-dose inhalers Rapid onset of bronchodilation (Ventolin: within 5 minutes) Sustained anti-inflammatory protection (Pulmicort: up to 12 hours) Multiple delivery device options including Turbuhaler and HFA inhalers Pre-measured doses for consistent administration Temperature-stable formulations Benefits Provides immediate relief from acute asthma symptoms while controlling underlying inflammation Reduces frequency and severity of asthma exacerbations Decreases reliance on rescue medication alone Improves lung function measurements (FEV1 and peak flow) Enhances quality of life through better symptom control May reduce airway remodeling when used consistently Common use This combination therapy is primarily indicated for patients with persistent asthma requiring both maintenance and rescue treatment.
Ventolin HFA 90 mcg Inhaler: Fast-Acting Asthma Relief
Ventolin HFA (albuterol sulfate) 90 mcg Inhaler is a prescription metered-dose inhaler indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. It is also indicated for the prevention of exercise-induced bronchospasm. This short-acting beta2-adrenergic agonist (SABA) works by relaxing the muscles in the airways, allowing for improved breathing within minutes. It is a cornerstone rescue medication in asthma management protocols and is approved by the U.
Advair Diskus: Comprehensive Asthma and COPD Control
Advair Diskus is a combination inhaled corticosteroid and long-acting beta2-adrenergic agonist (ICS/LABA) medication designed for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It delivers two complementary medications—fluticasone propionate and salmeterol—in a single, easy-to-use inhalation device. This dual-action formulation addresses both airway inflammation and bronchoconstriction, providing a foundational therapy for patients requiring more than a single-agent inhaler. Clinically proven to improve lung function and reduce exacerbations, it is indicated for patients aged 4 years and older with asthma and adults with COPD, including chronic bronchitis and/or emphysema.
Albuterol for Cough: Effective Relief for Bronchitis and Croup
Albuterol is a widely prescribed bronchodilator that offers targeted relief for respiratory conditions characterized by coughing, wheezing, and airway constriction. It is particularly effective in managing acute symptoms of bronchitis and croup, where inflammation and mucus production impair breathing. By relaxing the muscles around the airways, albuterol helps open constricted bronchial tubes, facilitating easier airflow and reducing cough severity. This medication is available in various forms, including inhalers and nebulizer solutions, allowing for flexible administration based on patient needs and clinical context.